Sanofi-Synthelabo/Bristol-Myers Squibb Plavix sNDA Has Feb. User Fee Goal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo and Bristol-Myers Squibb could see FDA action by February on their supplemental NDA for the antiplatelet agent Plavix. The application was submitted Aug. 21 and is being given priority review.